4.12.22-Health-Science-Jianzhu-Chen

• Video details

  Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor-engineered T (CAR-T) cells for treating hematological malignancies, there is a rapidly growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including (1) better safety, such as a lack of or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogeneic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for “off-the-shelf” manufacturing. We are developing the next generation of CAR-NK cells by combining tumor-specific CAR, additional armors, and cytokine-induced memory-like (CIML) NK cells, with a goal to achieve better tumor-specific targeting, enhanced proliferation and persistence in vivo, resistance to the suppressive tumor microenvironment, and ultimately an effective and durable anti-tumor response in patients.

Locked Interactive transcript